• As an adjunct in the therapy of all forms of parkinsonism (idiopathic, postencephalitic, arteriosclerotic)
• Control of extrapyramidal disorders secondary to neuroleptic drug therapy (e.g., phenothiazines)

Drug-Induced Extapyramidal Symptoms:

Oral: One tablet one to three times daily.

Parkinson's Disease: Oral: The usual beginning dose is one tablet three or four times daily. The dosage should be individualized with the dose titrated upward to a maximum of 8 tablets (16 mg) per 24 hours.

AKINETON (biperiden hydrochloride) Tablets, 2 mg each, white, embossed on one face with a triangle, bisected on the reverse and imprinted with the number "11." Bottles of 100 - NDC # 49884-693-01

Storage: Store at 25°C (77°F); excursions permitted to 15- 30°C (59-86°F) [see USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in USP.

AKINETON is a registered trademark of Knoll AG.

03-5161-R1 Revised: November, 2001

Manufactured for:
PAR PHARMACEUTICAL, INC.
Spring Valley, New York 10977

Manufactured by:
ABBOTT LABORATORIES
NORTH CHICAGO, IL 60064, U.S.A.

Bookmark this page: